| Cassius Mining Limited (CMD) ORDINARY FULLY PAID |
Materials |
$21 |
Loyalty Issue of Bonus Options to Shareholders
|
12 Jun 2026 9:49AM |
$0.033 |
$0.028 |
fallen by
15.15%
|
|
CMD - Price-sensitive ASX Announcement
Full Release
Key Points
- Pro-rata bonus issue of 1 new option for every 8 ordinary shares.
- Options with an exercise price of 3 cents, expiring on 8 June 2029.
- No funds will be raised, aims to reward shareholders.
- Eligible only for shareholders in Australia and New Zealand.
- The entitlements are non-renounceable.
- Intention to apply for ASX quotation of new options.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Thorney Technologies Ltd (TEK) ORDINARY FULLY PAID |
Financials |
$35 |
Update - Notification of buy-back - TEK
|
12 Jun 2026 9:49AM |
$0.090 |
$0.098 |
risen by
8.89%
|
|
| Digico Infrastructure REIT (DGT) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,480 |
DigiCo Contracts LAX Sale
|
12 Jun 2026 9:48AM |
$2.520 |
$2.650 |
risen by
5.16%
|
|
| Microba Life Sciences Limited (MAP) ORDINARY FULLY PAID |
Health Care |
$29 |
Reinstatement to Quotation
|
12 Jun 2026 9:46AM |
$0.063 |
$0.041 |
fallen by
34.92%
|
|
MAP - Price-sensitive ASX Announcement
Full Release
Key Points
- The suspension of trading in Microba Life Sciences Limited's securities will be lifted immediately.
- This follows the release of an announcement regarding a material capital raise.
- Microba also provided an update on its path to break even.
- The reinstatement to quotation is issued by ASX Compliance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID |
Health Care |
$4 |
Trading Halt
|
12 Jun 2026 9:46AM |
$0.260 |
$0.015 |
fallen by
94.23%
|
|
CYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Cynata Therapeutics Limited requests trading halt for its securities.
- Trading halt pending announcement of clinical trial results.
- Phase 3 Osteoarthritis Trial and Phase 2 Graft Versus Host Disease Trial results pending.
- Trading halt to last until 16 June 2026 or earlier announcement.
- Company not aware of reasons against trading halt.
- Trading halt in accordance with ASX Listing Rule 17.1.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Microba Life Sciences Limited (MAP) ORDINARY FULLY PAID |
Health Care |
$29 |
Proposed issue of securities - MAP
|
12 Jun 2026 9:46AM |
$0.063 |
$0.041 |
fallen by
34.92%
|
|
| Microba Life Sciences Limited (MAP) ORDINARY FULLY PAID |
Health Care |
$29 |
Proposed issue of securities - MAP
|
12 Jun 2026 9:46AM |
$0.063 |
$0.041 |
fallen by
34.92%
|
|
| Microba Life Sciences Limited (MAP) ORDINARY FULLY PAID |
Health Care |
$29 |
Proposed issue of securities - MAP
|
12 Jun 2026 9:46AM |
$0.063 |
$0.041 |
fallen by
34.92%
|
|
| Microba Life Sciences Limited (MAP) ORDINARY FULLY PAID |
Health Care |
$29 |
Proposed issue of securities - MAP
|
12 Jun 2026 9:46AM |
$0.063 |
$0.041 |
fallen by
34.92%
|
|
| WAM Strategic Value Limited (WAR) ORDINARY FULLY PAID |
Financials |
$200 |
May 2026 Investment Update
|
12 Jun 2026 9:46AM |
$1.075 |
$1.110 |
risen by
3.26%
|
|
| Microba Life Sciences Limited (MAP) ORDINARY FULLY PAID |
Health Care |
$29 |
Investor presentation - path to cashflow breakeven
|
12 Jun 2026 9:46AM |
$0.063 |
$0.041 |
fallen by
34.92%
|
|
MAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Path to cashflow break-even by CY2027.
- Strong sales growth in core testing products.
- New product launch planned for Q3 CY26.
- Equity raise to fund growth and new initiatives.
- Marketable addressable market of $25B for GI solutions.
- AI efficiency and infrastructure investment driving operational leverage.
- Potential partnerships in the therapeutics sector.
- Serviceable addressable market of 18.6 million tests annually in key markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Microba Life Sciences Limited (MAP) ORDINARY FULLY PAID |
Health Care |
$29 |
$5M secured to deliver cashflow breakeven and testing growth
|
12 Jun 2026 9:45AM |
$0.063 |
$0.041 |
fallen by
34.92%
|
|
MAP - Price-sensitive ASX Announcement
Full Release
Key Points
- $5 million placement secured at $0.05 per share.
- Investment includes $1.5 million from Sonic Healthcare Limited.
- Path to cashflow break-even by CY2027 through AI-driven efficiencies.
- 11 consecutive quarters of core testing sales growth.
- 106% growth in core testing sales over the last 12 months.
- Launch of a new category-defining testing product in Q3 CY26.
- Shareholders can apply for up to $30,000 of new shares under the SPP.
- Attaching options exercisable at $0.0625 expiring in three years.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rokeby Resources Limited (RKB) ORDINARY FULLY PAID |
Materials |
$12 |
Change of Director's Interest Notice
|
12 Jun 2026 9:44AM |
$0.003 |
$0.004 |
risen by
33.33%
|
|
| Thorney Opportunities Ltd (TOP) ORDINARY FULLY PAID |
Financials |
$93 |
Net Tangible Asset Backing May 2026 with commentary
|
12 Jun 2026 9:43AM |
$0.505 |
$0.555 |
risen by
9.90%
|
|
| Electro Optic Systems Holdings Limited (EOS) ORDINARY FULLY PAID |
Industrials |
$1,831 |
Update - Proposed issue of securities - EOS
|
12 Jun 2026 9:42AM |
$9.470 |
$8.260 |
fallen by
12.78%
|
|
| Blackwall Limited (BWF) ORDINARY FULLY PAID |
Financials |
$23 |
Change of Director's Interest Notice
|
12 Jun 2026 9:41AM |
$0.150 |
$0.135 |
fallen by
10%
|
|
| Megaport Limited (MP1) ORDINARY FULLY PAID |
Information Technology |
$4,816 |
Application for quotation of securities - MP1
|
12 Jun 2026 9:40AM |
$18.700 |
$20.400 |
risen by
9.09%
|
|
| Electro Optic Systems Holdings Limited (EOS) ORDINARY FULLY PAID |
Industrials |
$1,831 |
Completion and Upsize of Share Purchase Plan
|
12 Jun 2026 9:39AM |
$9.470 |
$8.260 |
fallen by
12.78%
|
|
EOS - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of Share Purchase Plan (SPP) by EOS.
- SPP initially targeted $25 million, increased to $40 million.
- Conducted alongside $150 million institutional and $40 million strategic placements.
- Received $95 million in applications from 4,909 shareholders.
- Pro-rata scale-back applied, ensuring minimum $1,000 parcel for shareholders.
- New shares priced at $8.00, same as placements.
- Issue date for new shares is 16 June 2026; trading starts 17 June 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Woodside Energy Group Ltd (WDS) ORDINARY FULLY PAID |
Energy |
$56,900 |
Woodside exercises Browse pre-emption right
|
12 Jun 2026 9:38AM |
$31.520 |
$29.930 |
fallen by
5.04%
|
|
WDS - Price-sensitive ASX Announcement
Full Release
Key Points
- Woodside exercises its pre-emption right to acquire CNPC's 10.67% interest in the Browse Joint Venture.
- The acquisition terms include a payment of US$225 million to CNPC and a contingent payment of US$175 million.
- Woodside's equity interest in the Browse Joint Venture will increase to 41.27%.
- The Browse resource is Australia's largest undeveloped conventional gas resource with potential production of 11.4 million tonnes per annum of LNG, LPG, and domestic gas.
- The acquisition is part of Woodside's strategy to maximize long-term shareholder value and align integrated value for a development with long-term cash flow potential.
- Woodside plans to work with the Browse Joint Venture to evaluate development opportunities, including technical definition, commercial arrangements, and regulatory approvals.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ceryvyn Therapeutics Limited (OPT) ORDINARY FULLY PAID |
Health Care |
$18 |
Revised Webinar Details and Investor Presentation
|
12 Jun 2026 9:37AM |
$0.014 |
$0.013 |
fallen by
7.14%
|
|
| SPC Global Holdings Ltd (SPG) ORDINARY FULLY PAID |
Consumer Staple |
$118 |
Becoming a substantial holder
|
12 Jun 2026 9:34AM |
$0.100 |
$0.099 |
fallen by
1%
|
|
| Adheris Health Limited (AHE) ORDINARY FULLY PAID |
Health Care |
$11 |
Appointment of John Murray as Non-Executive Director
|
12 Jun 2026 9:34AM |
$0.019 |
$0.017 |
fallen by
10.53%
|
|
| Vitrafy Life Sciences Limited (VFY) ORDINARY FULLY PAID |
Health Care |
$175 |
Proposed issue of securities - VFY
|
12 Jun 2026 9:33AM |
$3.800 |
$2.810 |
fallen by
26.05%
|
|
| SPDR S&P 500 ETF Trust (SPY) |
Financials |
$405 |
Distribution Record Date Announcement
|
12 Jun 2026 9:33AM |
$1,039.760 |
$1,078.750 |
risen by
3.75%
|
|
| Vitrafy Life Sciences Limited (VFY) ORDINARY FULLY PAID |
Health Care |
$175 |
Vitrafy Equity Raising Presentation
|
12 Jun 2026 9:33AM |
$3.800 |
$2.810 |
fallen by
26.05%
|
|
VFY - Price-sensitive ASX Announcement
Full Release
Key Points
- Vitrafy is conducting a non-underwritten institutional placement to raise approximately $30 million.
- The placement price is $2.60 per share, representing a 31.6% discount to the last close price.
- Funds raised will be used for manufacturing, US operations, and sales and marketing activities.
- Vitrafy plans to scale its operational cryopreservation device fleet in the U.S.
- The company will also launch a share purchase plan to raise an additional $2 million.
- Vitrafy faces risks such as commercialisation challenges and funding needs.
- The company has limited operating history and relies on key relationships.
- Vitrafy is developing a cryopreservation technology for various applications.
- The company aims to expand into U.S. markets with new devices.
- Vitrafy aims to address supply shortages in cryopreserved blood products.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
